Clinical and epidemiologic burden of chronic myelogenous leukemia.
about
The role of observational studies in optimizing the clinical management of chronic myeloid leukemiaSuccessful pregnancy in a patient with chronic myeloid leukaemia exposed to dasatinib during the first trimester.Changing trends of chronic myeloid leukemia in greater Mumbai, India over a period of 30 years.Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemiaManagement of Bcr-Abl-positive leukemias with dasatinib.Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study.Molecular techniques for the personalised management of patients with chronic myeloid leukaemia.Detection of BCR-ABL Positive Cells in an Asymptomatic Patient: A Case Report and Literature Review.Model-based cost-effectiveness analyses for the treatment of chronic myeloid leukaemia: a review and summary of challenges.Report of chronic myeloid leukemia in chronic phase from Dr. Senthil Rajappa, 2002-2009.Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance.Hematologic malignancies: an opportunity to fill a gap in cancer surveillance.Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted nations.
P2860
Q28085149-3A338A36-4B34-41B6-9887-2DA1BE173D70Q34523506-81FD5924-9FE4-41F3-803C-2B3D57DD6CD7Q35610886-89113BA3-BCED-4961-9314-A74C9B457254Q36462473-9D335591-8362-4660-8E8F-84845E55BA9CQ37004660-F64FD6DA-39AB-4A0B-8AE7-F057AC513031Q37013074-3B6413BA-4197-4B78-90C9-8E85A1AB111AQ37418952-88C9A103-ABA8-4C02-A41C-9AF7480AC8A9Q37696776-CCF8D1A0-64AA-4ADB-B572-EACF94628653Q37698231-137B105D-3B8F-406C-9EBF-0B36434D7F6AQ38218300-228C6C30-884D-49B3-A260-5EDB23B644AFQ41859999-77772980-5246-4FE9-AFC7-8C1F78F7FB1CQ42409714-D24FB606-8B8E-4D85-A04B-CE3B7D400E55Q43676080-9402E32A-737E-4B95-910C-04FF83AF7734Q47767989-6EB78777-A7F0-4CE7-A919-E7AE88A93CCFQ53087755-E5897920-0784-4E0D-A3B8-8CEEFEF2F0E2
P2860
Clinical and epidemiologic burden of chronic myelogenous leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical and epidemiologic burden of chronic myelogenous leukemia.
@ast
Clinical and epidemiologic burden of chronic myelogenous leukemia.
@en
type
label
Clinical and epidemiologic burden of chronic myelogenous leukemia.
@ast
Clinical and epidemiologic burden of chronic myelogenous leukemia.
@en
prefLabel
Clinical and epidemiologic burden of chronic myelogenous leukemia.
@ast
Clinical and epidemiologic burden of chronic myelogenous leukemia.
@en
P2093
P2860
P356
P1476
Clinical and epidemiologic burden of chronic myelogenous leukemia.
@en
P2093
Alberto Redaelli
Benjamin Laskin
Chris Pashos
Christopher Bell
Jennifer Stephens
Jodie Casagrande
Marc Botteman
P2860
P356
10.1586/14737140.4.1.85
P577
2004-02-01T00:00:00Z